Anti-SLC34A2 (Lifastuzumab) -SMCC-DM1

Anti-SLC34A2 (Lifastuzumab) -SMCC-DM1 is an antibody-drug conjugate (ADC) consisting of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody Lifastuzumab (HY-P99970) conjugated to the linker SMCC (HY-42360) and the the cytotoxic microtubule inhibitor DM1 (HY-19792) . The ADC toxic molecule and linker part are SMCC-DM1 (HY-101070) . Anti-SLC34A2 (Lifastuzumab) -SMCC-DM1 can be used in the research of cancer[1][2].

Product Specifications

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs) ; Microtubule/Tubulin; Sodium Channel

Related Pathways

Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton; Membrane Transporter/Ion Channel

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

[Anti-SLC34A2(Lifastuzumab)-SMCC-DM1]

References & Citations

[1]Banerjee S, et al. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Ann Oncol. 2018 Apr 1;29 (4) :917-923.|[2]Shao S, et al. Site-specific and hydrophilic ADCs through disulfide-bridged linker and branched PEG. Bioorg Med Chem Lett. 2018 May 1;28 (8) :1363-1370.